| DB ID | MyCo_3136 |
| Title | Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma |
| Year | 2020 |
| PMID | 32759935 |
| Fungal Diseases involved | Diffuse large B cell lymphoma (DLBCL) |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The institutional review board and the ethic committee of Memorial Sloan Kettering Cancer Center (MSKCC) granted approval for conducting the study. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | None |
| Sample source | None |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CD19-targeted chimeric antigen receptor (CAR) T cell |
| Biomarker Full Name | CD19-targeted chimeric antigen receptor (CAR) T cell |
| Biomarker Type | Predictive |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | The study cohort included 60 consecutive patients with RR DLBCL who received FDA-approved CAR T cell therapy (axicabtagene ciloleucel—Yescarta; Kite Pharma, Santa Monica, CA or tisagenlecleucel—Kymriah; Novartis, Basel, Switzerland) at MSKCC between January 2018 and June 2019. Baseline clinical characteristics, patterns of antimicrobial prophylaxis, treatment of infection, and laboratory data, including blood count, CD4 lymphocyte, and immunoglobulin (Ig) level before lymphodepletion (LD) chemotherapy were abstracted from the electronic health records (EHR). Systemic bridging therapy were classified to intensive or non-intensive regimens. Intensive regimens included multi-agent immunochemotherapy e.g. CHOP-like, bendamustine-based, gemcitabinebased, high dose cytarabine-based, and ICE regimens. Non-intensive regimens included single-agent rituximab, immunomodulatory agent or small molecule inhibitor. The LD chemotherapy before CAR T cell infusion was selected based on recommended regimens in the package insert of each approved CAR T product. In patients who received axicabtagene ciloleucel, LD chemotherapy consisted of fludarabine 30 mg/m2, and cyclophosphamide 500 mg/m2 daily for 3 days. For patients receiving tisagenlecleucel, fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 daily for 3 days or bendamustine 90 mg/m2 daily for 2 days was given for LD. |
| Cohort No. | 60 Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | CD19-directed chimeric antigen receptor (CAR) T cell is a major breakthrough that has revolutionized the treatment paradigm of relapsed/refractory (RR) diffuse large B cell lymphoma (DLBCL) over the past recent years. Despite the significant anti-lymphoma activity, CD19 CAR T cells possess unique toxicities. Besides immune-mediated toxicities, B cell aplasia, and resultant hypogammaglobulinemia are common consequences of CD19 CAR T cell therapy, which put patients at risk for infectious complications. Although there have been some initial reports on the infectious complications of CAR T cell therapy, most studies included patients treated in clinical trials or with multiple underlying B cell malignancies. Currently, there are limited real-world data on infectious risks in patients treated with CD19 CAR T cell therapy for DLBCL. Moreover, little is known about proper prophylaxis and management strategies for these patients. Herein, we describe the pattern, incidence, impact of infections, including infection prophylactic strategies, in patients with DLBCL who received FDAapproved CAR T cell therapy at Memorial Sloan Kettering Cancer Center (MSKCC). |
| Technique | Analytic |
| Analysis Method | FDA Approved Therapy |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA Approved Therapy |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
